Digital pathology market seen reaching $1.79 billion by 2030

A new Allied Market Research report says the global digital pathology market will grow from $735.75 million in 2020 to $1.79 billion by 2030 as AI, remote diagnosis and digitalization reshape lab workflows. The forecast points to strong demand in disease diagnosis and scanners, even as high costs and reimbursement gaps slow adoption.

Why it matters: - Digital pathology is moving from a niche lab tool to a core part of disease diagnosis, with implications for faster reads, remote consultation and broader access to pathology services. - The market forecast signals continued investment in AI-enabled diagnostics and digital workflows across healthcare providers and technology vendors. - The report projects the global digital pathology market will reach $1,791.30 million by 2030, up from $735.75 million in 2020. - That works out to a compound annual growth rate of 9.3% from 2021 to 2030.

What happened: - Allied Market Research released a report on the global digital pathology market on June 10, 2026. - The report highlights demand from disease diagnosis, medical digitalization, easier consultation and growth in diagnostic services in remote regions. - The report also names Leica Biosystems, Philips Healthcare, Roche Diagnostics, 3DHISTECH and Hamamatsu Photonics among key players. - The report is available through a sample PDF request.

The details: - Digital pathology systems include scanners that convert glass slides into high-resolution images, plus image analysis software and storage tools. - AI-driven software supports image analysis by identifying patterns and anomalies in tissue samples. - Telepathology enables remote viewing and analysis of pathology images across locations. - Storage and management systems can be cloud-based or on-premise. - The scanner segment held more than two-thirds of the global market in 2020 and is projected to post the fastest CAGR at 9.6% through 2030. - The disease diagnosis segment held more than one-third of the market in 2020 and is expected to grow at a 9.8% CAGR from 2021 to 2030. - North America held nearly half the global market in 2020. - Asia-Pacific is projected to grow the fastest, with a 10.6% CAGR by 2030. - Europe and LAMEA are also covered in the report. - The report lists drivers including advances in AI and machine learning, rising cancer prevalence, regulatory approvals and workflow efficiency gains. - The report identifies high upfront costs, uneven regulation and data security and privacy concerns as key challenges. - The report points to AI integration, cloud-based storage and partnerships between technology companies and healthcare providers as major trends. - The report names 3DHISTECH LTD, Danaher Corporation, Glencoe Software, Hamamatsu Photonics K.K., Indica Labs, Koninklijke Philips N.V., Nikon Corporation, Roche, VisoPharma A/S and PerkinElmer Inc. among top companies.

Between the lines: - The forecast suggests buyers are still weighing a clear payoff from digital pathology against capital expense and compliance hurdles. - Faster growth in Asia-Pacific points to expanding adoption outside North America, where the market already has the largest base. - AI and cloud capabilities appear to be the biggest differentiators as pathology labs look for speed, scale and collaboration. - The emphasis on regulatory approvals suggests market confidence is being shaped as much by validation as by technology performance.

What's next: - The report expects continued growth through 2030 as AI tools improve and digital workflows spread. - Market expansion will likely depend on reimbursement policy, lower system costs and stronger data protection. - Providers and vendors are expected to keep building partnerships to support deployment and adoption. - Interested buyers can submit a purchase enquiry for the full report.

The bottom line: - Digital pathology is on a steady growth path, but the next phase of adoption will hinge on cost, reimbursement and trust in digital systems.